Mening 01 Poehling 508

CDC ACIP — Vaccine Advisory Committee

Acip

Slides

8

Download PDF ↗ Live URL (may be dead)

Document text

National Center for Immunization & Respiratory Diseases 
ACIP Meningococcal Vaccines Work Group 
Introduction 
Katherine Poehling, MD, MPH 
Work Group Chair 
February 23, 2023 
   
 
  
 
 
  
  
 
  
 
  
  
   
  
 
 
  
 
    
 
  
  
  
  
  
  
   
  
  
   
  
  Meningococcal Vaccines Work Group 
 ACIP Members 
– Kat
herine Poehling (Chair) 
– Lynn Bahta 
– Jam
ie Loehr 
 Ex Officio Members 
– Mar
garet Bash (FDA) 
– Mark Connelly (FDA) 
– Fra
ncisco Leyva (NIH) 
 CDC Lead 
– Sam Crowe (DBD/NCIRD) 
 Liaisons and Consultants 
– A
mra Resic (AAFP) 
– Samir Shah (AAP) 
– Sharon McMullen (ACHA) 
– Cacky Tate (AIM) 
– Paul Cieslak (CSTE) 
– Jeff Goad (NFID) 
– Jessica Cataldi (PIDS) 
– Amy Middleman (SAHM) – David Stephens (Emory) 
 CDC Contributors 
– L
eAnne Fox (DBD/NCIRD) 
– Susan Hariri (DBD/NCIRD) 
– Lucy McNamara (DBD/NCIRD) 
– Alison Albert (DBD/NCIRD) 
– Noele Nelson (DBD/NCIRD) 
– Jonathan Duffy (DHQP/NCEZID) 
– Tanya Myers (DHQP/NCEZID) 
– Ismael Ortega-Sanchez (DVD/NCIRD) 
– Liz Velazquez (ISD/NCIRD) 
– Jessica MacNeil (ACIP Secretariat) 
 GRADE/EtR 
– D
oug Campos-Outcalt (Arizona) 
– Rebecca Morgan (McMaster) 
2 
   
  
      
   
 
 October ACIP Meeting Recap 
 Menveo one-vial presentation 

 Introduction to the two new MenABCWY vaccines 
–
 Manufacturers: GSK and Pfizer 
– Policy questions 
– PICOs 
– Next steps 
3 
   
       
    Work Group Schedule Updates 
Task 2022 2023 2024 
6 7 8 9 10 11 12 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3 4 5 6 
Menveo Solution 
Pfizer Pentavalent Vaccine 
GSK Pentavalent Vaccine 
4 
    
        
  
 
   
   
     
  
  Proposed Timeline of ACIP Presentations 
February 
2023 June 
2023 October 
2023 
• Epidemiology of • Pfizer GRADE, EtR, • Pfizer vote 
meningococcal and cost study 
• GS
K GRADE, EtR, di
sease 
• GS
K trial data and cost study 
• Pf
izer trial data 
5 
     
           
  
        
          
    
     
      Summary of Recent Work Group Activities 
 GSK and Pfizer presented on their pentavalent vaccines and work group 
asked clarifying questions 
 Work group discussed whether to reconsider adolescent immunization schedule 
 Decided to postpone any reviews of the schedule until after both pentavalent vaccines have been assessed 
– Vaccine reviews will be complex and challenging 
– Need to understand epidemiology of meningococcal disease after COVID-19 
6 
  
      
  
    
 
        
  Agenda for Today 
 Epidemiology of Meningococcal Disease in the United States 
–
 A
my Rubis, CDC 

 Pfizer’s MenABCWY Vaccine Clinical Trials Data 
–
 P
fizer Representative 

 Work Group Interpretation of Pfizer’s MenABCWY Vaccine Clinical Trials Data 
–
 Sam Crowe, CDC 
7 
    
 
      
                        
   For more information, contact CDC 
1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov 
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.